Compare AMCI & TVGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
| Metric | AMCI | TVGN |
|---|---|---|
| Founded | 2021 | 2020 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Blank Checks | Blank Checks |
| Sector | Finance | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 26.3M | 21.3M |
| IPO Year | 2022 | 2021 |
| Metric | AMCI | TVGN |
|---|---|---|
| Price | $0.82 | $5.69 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 130.9K | 7.8K |
| Earning Date | 11-16-2026 | 11-16-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $5,980,847.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.78 | $0.14 |
| 52 Week High | $15.75 | $24.91 |
| Indicator | AMCI | TVGN |
|---|---|---|
| Relative Strength Index (RSI) | 27.43 | 51.15 |
| Support Level | N/A | $6.15 |
| Resistance Level | $3.99 | $7.22 |
| Average True Range (ATR) | 0.28 | 0.40 |
| MACD | -0.01 | 0.08 |
| Stochastic Oscillator | 1.16 | 63.98 |
AMC Robotics Corp is a technology solutions company that offers AI-powered smart security and robotics solutions. It currently sells smart hardware products designed for residential and commercial use, including smart cameras, driving recorders, action cameras, and Retina K cameras, which are marketed under the YI brand. AMC Robotics is also engaged in developing additional hardware products and technology capabilities, including IoT-enabled devices, AI-based features, wearable devices, and AI robotics. Using its technological capabilities, the company is developing robotic dogs, robotic arms, and robotic unloading systems, offering smart solutions for the logistics and warehousing sectors. It has two primary operating segments: North America, which generates maximum revenue, and Europe.
Tevogen Bio Holdings Inc a clinical-stage specialty immunotherapy company harnessing CD8+ cytotoxic T lymphocytes (CD8+ CTLs or CTLs), to develop off-the-shelf, precision T cell therapies for the treatment of infectious diseases, cancers, and neurological disorders. The first clinical product of ExacTcell, TVGN 489, is initially being developed to fill a critical gap in COVID-19 therapeutics for the immunocompromised and the high-risk elderly, with potential applications in both treatment and prevention of chronic, lingering symptoms of the disease (Long COVID). Viruses, including COVID-19, hijack cellular machinery to transform infected cells into virus production plants.